PMID- 17311604
OWN - NLM
STAT- MEDLINE
DCOM- 20070629
LR  - 20220310
IS  - 0269-2813 (Print)
IS  - 0269-2813 (Linking)
VI  - 25
IP  - 6
DP  - 2007 Mar 15
TI  - Programme of stepping down from twice daily proton pump inhibitor therapy for 
      symptomatic gastro-oesophageal reflux disease associated with a formulary change 
      at a VA medical center.
PG  - 709-14
AB  - BACKGROUND: In July 2001, our Veterans' Affairs hospital changed its formulary 
      proton pump inhibitor (PPI) from lansoprazole to rabeprazole. All patients 
      previously receiving lansoprazole 30 mg twice daily were switched to rabeprazole 
      20 mg once daily. AIM: To determine if patients with gastro-oesophageal reflux 
      disease (GERD), who were previously managed on lansoprazole 30 mg twice daily, 
      could be maintained on rabeprazole 20 mg once daily. PATIENTS AND METHODS: Four 
      hundred and thirty-five patients had received lansoprazole 30 mg twice daily for 
      at least 12 months before the formulary change. Medical records were reviewed for 
      12 months before and after the formulary change. RESULTS: There were 432 men and 
      three women with a mean age of 66.7 years (range: 38-91). Two hundred and twelve 
      patients were excluded. Of the remaining 223, 111 (50%) were maintained 
      successfully on rabeprazole 20 mg once daily. Twenty-three (10%) stayed off all 
      acid suppression during follow-up. The number of endoscopies and clinic visits 
      did not significantly change during the follow-up. Fifty-six percent who had 
      erosive oesophagitis failed a dose taper compared with 31% of those with 
      endoscopy-negative GERD (P<0.025). CONCLUSIONS: Most patients receiving twice 
      daily PPI therapy for GERD could be maintained on once daily PPI or no acid 
      suppression for 12 months of follow-up. Dose reduction was more successful in 
      those without erosive oesophagitis.
FAU - Cote, G A
AU  - Cote GA
AD  - Division of Gastroenterology, Northwestern University Feinberg School of 
      Medicine, Chicago, IL 60611, USA.
FAU - Ferreira, M R
AU  - Ferreira MR
FAU - Rozenberg-Ben-Dror, K
AU  - Rozenberg-Ben-Dror K
FAU - Howden, C W
AU  - Howden CW
LA  - eng
PT  - Journal Article
PL  - England
TA  - Aliment Pharmacol Ther
JT  - Alimentary pharmacology & therapeutics
JID - 8707234
RN  - 0 (2-Pyridinylmethylsulfinylbenzimidazoles)
RN  - 0 (Anti-Ulcer Agents)
RN  - 0 (Proton Pump Inhibitors)
RN  - 0K5C5T2QPG (Lansoprazole)
RN  - 32828355LL (Rabeprazole)
SB  - IM
MH  - 2-Pyridinylmethylsulfinylbenzimidazoles/*administration & dosage/economics
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anti-Ulcer Agents/*administration & dosage/economics
MH  - Cost Savings
MH  - Esophagitis, Peptic/complications
MH  - Female
MH  - Formularies, Hospital as Topic
MH  - Gastroesophageal Reflux/complications/*drug therapy/economics
MH  - Humans
MH  - Lansoprazole
MH  - Male
MH  - Middle Aged
MH  - *Proton Pump Inhibitors
MH  - Rabeprazole
MH  - Treatment Failure
EDAT- 2007/02/22 09:00
MHDA- 2007/06/30 09:00
CRDT- 2007/02/22 09:00
PHST- 2007/02/22 09:00 [pubmed]
PHST- 2007/06/30 09:00 [medline]
PHST- 2007/02/22 09:00 [entrez]
AID - APT3248 [pii]
AID - 10.1111/j.1365-2036.2007.03248.x [doi]
PST - ppublish
SO  - Aliment Pharmacol Ther. 2007 Mar 15;25(6):709-14. doi: 
      10.1111/j.1365-2036.2007.03248.x.